Menu

Grant Opportunities

 

REQUEST FOR APPLICATIONS

 

Effect of Augmentation Therapy on COPD Exacerbations in Alpha-1 Antitrypsin Deficiency

Application Deadline: Monday, May 8, 2017

Amount of Grant: up to $500,000 ($250,000/year) over two (2) years to fund one (1) award.

Background: Given the uncertainty about the relationship between augmentation therapy and acute pulmonary exacerbations in alpha-1 antitrypsin deficiency-associated COPD, there is a need for a prospective placebo-controlled study designed to assess the effect of augmentation therapy on exacerbations. A definitive answer to this question is of considerable importance to investigators in view of the demonstrated impact of exacerbations on health status and the need to improve the patients’ health-related quality of life. The definition of exacerbations has varied in previous investigations and may in part explain the inconsistent results. It is therefore important to clearly articulate the criteria used to define the presence, severity and duration of pulmonary exacerbations in future studies.

The purpose of this RFA is to assess the effect of intravenous augmentation therapy compared to placebo on acute pulmonary exacerbations (frequency and/or severity and/or time to first exacerbation) in patients with severe alpha-1 antitrypsin deficiency (serum alpha-1 antitrypsin level <50mg/dl when clinically stable).

Click to Access ProposalCentral

 

Gordon L. Snider Scholar Award

Application Deadline: Monday, April 3, 2017

Amount of Grant: up to $225,000 ($75,000/year) over three (3) years to fund two (2) awards

This award is named after Dr. Gordon L. Snider, one of the most influential researchers in Alpha–1 Antitrypsin Deficiency (AATD). Dr. Snider not only made seminal scientific contributions which have clarified the pathogenesis of AATD, but also laid the groundwork for the Foundation’s research program. In particular, he stressed the importance of encouraging young investigators to pursue a career in AATD research.

The objective of this award is to provide additional career development support for outstanding young investigators who have continued to conduct research (basic or clinical) in AATD related lung or liver disease after completion of their postdoctoral fellowship. It is expected that the award will provide an incentive for a career in AATD research.

Snider, who died on June 8, 2013 at age 91, founded the pulmonary section of the Boston University School of Medicine and was chief of medical service at the Boston VA Medical Center for 14 years. He served for a decade on the Alpha–1 Foundation’s board of directors. He also served as president of the American Thoracic Society.

“Gordon spent virtually his entire career mentoring young investigators,” said his widow, Sally Everett. “He would be proud.”

For more information and how to apply.

 

MATCHING GRANT OPPORTUNITIES

CHEST Foundation and the Alpha–1 Foundation Research Grant in Alpha–1 Antitrypsin Deficiency:

Application Deadline: Friday, March 31, 2017

Amount of Grant: up to $25,000 over one (1) year

2017 marks the 11th year of the successful partnership between the CHEST Foundation and Alpha–1 Foundation in sponsoring a 1-year clinical research grant in alpha–1 antitrypsin (AAT) deficiency. The Alpha–1 Foundation is committed to finding a cure for alpha–1 antitrypsin (AAT) deficiency and to improving the lives of people affected by alpha–1 worldwide. Its grants and awards programs fund a broad range of research that leads to improvements in the health and quality of life of people living with AAT.

For more information and how to apply.

 

The Alpha–1 Foundation and the American Lung Association Alpha–1 Research Grant

Application Deadline: Thursday, April 6, 2017

Amount of Grant: up to $40,000 per year over two (2) years

This grant opportunity was created to encourage research on advancing the understanding of Alpha–1 Antitrypsin Deficiency and to support clinical, laboratory, epidemiological or any other kind of research projects aimed at developing novel medical treatments, advancing current treatment options or finding a cure for Alpha–1.

For more information and how to apply.

 

IN-CYCLE GRANT OPPORTUNITY INFORMATION

Letter of Intent

The first step in the process of a grant application to the Alpha-1 Foundation is to submit a Letter of Intent (LOI). The submission of an LOI is required for each grant category. An applicant must submit an LOI in order to submit a grant application. A grant application that is submitted without an LOI will result in an automatic denial of funding and the application will be returned to the investigator.

Application Timeline for 2016-2017 In-Cycle Grants

Deadline and Where to Submit

With the exception of Scientific Meeting Sponsorship Grants and Travel Grants, the Alpha-1 Foundation requires all applicants to submit their LOI using the online application form available on ProposalCentral.

The LOI must be submitted on ProposalCentral by Friday, September 16, 2016, 11:59pm EDT.

Click to Access ProposalCentral

Note: Applicants must create a profile and be logged in to ProposalCentral in order to access the Alpha-1 Foundation’s LOI Form.

For detailed instructions on preparing your LOI application, please download the Alpha-1 Foundation’s LOI Application Instructions.


Inquiries or technical issues regarding ProposalCentral and the online application process should be directed to consumer support at:

Phone: 703-964-5840, Toll-free phone: 1-800-875-2562

Email: pcsupport@altum.com
 

Live customer support is only available from 8:30am – 5pm ET.

Research FAQs 

For information about the Foundation’s in-cycle grant opportunities, please contact David Fernandez, Director of Research Administration, at dfernandez@alpha1.org or call (877) 228-7321 ext. 242.

Grant Application

If your LOI is approved, the Alpha-1 Foundation will invite you to submit a full grant application. Please note that a LOI must be submitted, reviewed and approved prior to submitting a grant application. Click the following links for information and instructions regarding the submission of a grant application:

For information about the Alpha-1 Foundation’s in-cycle grant application process or requirements, please contact David Fernandez, Director of Research Administration, at dfernandez@alpha1.org or (877) 228-7321 ext. 242.

Divider

In-Cycle Research Grant Categories:

Bridge Grantplus

Funding Level: Maximum of $25,000 may be requested.

Period: Up to 1 year of support is available.

The objective of this grant is to provide support for excellent Alpha-1 Antitrypsin (AAT) Deficiency-related research projects that have been submitted to and approved by the National Institutes of Health (NIH), but cannot be supported by the available NIH funds. Thus, this award complements the granting mechanism of the NIH for projects of potential interest to individuals served by the Alpha-1 Foundation. Funds provided by the Alpha-1 Foundation through this program are intended to lead to the development of sufficient preliminary data to make AAT-related applications highly competitive in the NIH review process. Information derived from Alpha-1 Foundation supported research studies is intended to lead to solicitation of additional, subsequent funds from other agencies such as the NIH.

Pilot and Feasibility Grantplus

Funding Level: Maximum of $40,000 may be requested.

Period: Up to 1 year of support is available.

The objective of this grant is to provide funds to encourage the development and testing of new hypotheses and/or new methods in research areas relevant to AAT Deficiency. Proposed work must be hypothesis generating or hypothesis testing, reflecting innovative approaches to important questions in AAT research or development of novel methods, and providing sufficient preliminary data to justify the Foundation’s support. Results from Pilot and Feasibility Grants should lead to the submission of applications for funding from other agencies (i.e. NIH). At the conclusion of the funding term, applicants are expected to apply for further funding by other mechanisms or from outside agencies. The award is not intended to support continuation of programs begun under other granting mechanisms.

Postdoctoral Research Fellowship Grantplus

Funding Level: Maximum of $50,000 per year may be requested.

Period: Up to 2 years of support is available.

The objective of this grant is to provide support for postdoctoral research fellows who are starting their research careers and are working in the laboratories of established researchers or conducting research with the mentorship of established researchers. In addition, this grant category is intended to provide support for postdoctoral research fellows who intend to pursue a career in AAT research. Applications will be accepted from candidates holding an M.D., Ph.D. or equivalent degrees who are interested in conducting basic science, clinical research, or ethic, legal, social issues studies related to AAT Deficiency. Applicants must indicate a commitment to AAT-related research by focusing 50% of their time to AAT Deficiency research or clinical practice.

Research Grantplus

Funding Level: Maximum of $100,000 per year may be requested.

Period: Up to 2 years of support is available.

The objective of this grant is to provide funds to encourage the development of new information that contributes to the understanding of the basic biology of AAT expression, and the pathogenesis/management of AAT Deficiency. In addition, consideration will be given to those projects that provide insight into the development of information that may contribute to new therapies for AAT Deficiency. All proposals must be hypothesis generating or hypothesis testing and provide sufficient preliminary data to justify the Alpha-1 Foundation’s support.

Scientific Meeting Sponsorship Grantplus

Funding Level: Grants are generally funded at the $5,000 level. The funds are restricted for use during a specified period of time.

Period: Varies according to request.

The objective of this grant is to provide support for scientific meetings, workshops or conferences relevant to AAT Deficiency and the Alpha-1 Foundation’s mission statement.

Please contact David Fernandez, Director of Research Administration, at dfernandez@alpha1.org or (877) 228-7321 ext. 242, for information on how to apply for a Scientific Meeting Sponsorship Grant.

Travel Grantplus

Funding Level: Grants are generally funded at a level of $1,000. The funds are restricted for use during a specified period of time.

Period: Varies according to request.

There are 2 types of Travel Grants:

  • The Alpha-1 Foundation provides funds to support travel to attend a scientific conference or meeting to present AAT-related abstracts or posters at national and international meetings. Candidates must have an M.D., Ph.D. or equivalent degree, and at least one year of recent research experience related to AAT Deficiency. The award is intended primarily for travel support for an award recipient. If the grant is to be used for specialized training, a letter of support for the individual must be presented, and clearly indicate the visitor’s role, time commitment and objectives for the proposed training as well as institutional commitment.

  • The Alpha-1 Foundation provides funds to support cross training at an established Alpha-1 laboratory by an established Alpha-1 investigator. Training may include training on diagnostic and therapeutic procedures, research related techniques, training on specialized equipment or software applicable to AAT-related research.

Please contact David Fernandez, Director of Research Administration, at dfernandez@alpha1.org or (877) 228-7321 ext. 242, for information on how to apply for a Travel Grant.

Divider

OUT-OF-CYCLE GRANT OPPORTUNITIES

The purpose of this program is to support large, typically clinical grants that do not fit into the in-cycle grant program. Out-of-cycle grants can be Foundation-initiated RFA or Investigator-initiated applications. The investigator should contact the Foundation before considering applying for an out-of-cycle application.

Please contact David Fernandez, Director of Research Administration, at dfernandez@alpha1.org or (877) 228-7321 ext. 242, for information about the Foundation's out-of-cycle grant opportunities.